Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis

• 来源期刊: 中国科学基金（英文版）
• 年，卷（期）: 2019,（1）
• 页码范围: 30
• 页数: 1页
• 语种: 英文

摘要

An international research team with multi-discipline expertise directed by Prof.Cui Rutao (major in biology) at the School of Medicine Boston University,Prof.Deng XianMing (邓贤明,major in medicinal chemistry) at the School of Life Sciences,Xiamen University,and Prof.Wang Peng (王鹏,major in clinical research) at Shanghai Cancer Center,Fudan University,recently reported a novel and viable therapeutic strategy for melanomas harboring NRAS mutations,which was published in Cell (2019,176:1113-1127.e16.).Both Prof.Deng and Wang received funding support from the National Natural Science Foundation of China for this work.